Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$46.83 USD

46.83
2,882,076

-0.93 (-1.95%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $46.82 -0.01 (-0.02%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Growing Testing Capacity to Aid LabCorp's (LH) Q2 Earnings?

by Zacks Equity Research

LabCorp's (LH) developments to support COVID-19 testing are believed to have contributed to the company's second-quarter earnings.

Zacks Equity Research

Amedisys Rides on Coronavirus-Led Business Amid Cost Woes

by Zacks Equity Research

Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.

Zacks Equity Research

Quest Diagnostics Gets EUA for Coronavirus Sample Pool Testing

by Zacks Equity Research

Quest Diagnostics (DGX) is riding high on a slew of EUAs for the expanded use of its self-collection molecular diagnostic kit on different platforms.

Zacks Equity Research

Testing Volume to Aid Quest Diagnostics' (DGX) Q2 Earnings?

by Zacks Equity Research

Looking at this demand for testing, Quest Diagnostics (DGX) has significantly picked up capacity to perform molecular diagnostic tests a day.

Zacks Equity Research

What's in Store for West Pharmaceutical's (WST) Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical Services (WST) is likely to have gained from continued strength in high-value product sales in Q2.

Zacks Equity Research

What's in the Cards for Intuitive Surgical (ISRG) Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment and decline in da Vince procedure volume.

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?

by Zacks Equity Research

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

Zacks Equity Research

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from continued strength in Clear Aligner shipment volumes in Q2.

Zacks Equity Research

Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

The rest of businesses within Life-Science Solutions segment of Thermo Fisher (TMO) are likely to have registered strong quarterly growth led by genetic sciences and bio production businesses.

Zacks Equity Research

OrganiGram (OGI) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and product launches in the fiscal third quarter despite pandemic-hit business conditions.

Zacks Equity Research

Why Is Exact Sciences (EXAS) Up 2.4% Since Last Earnings Report?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Exact Sciences' (EXAS) Q1 Earnings Fall Y/Y, Margin Expands

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.

Zacks Equity Research

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of -5.26% and 0.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

5 Hot Earnings Charts This Week

by Tracey Ryniec

Finance, travel and healthcare. How will these industries survive the coronavirus crisis?

Zacks Equity Research

How Hard Will Coronavirus Hit Zimmer Biomet (Zbh) Q1 Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) may have registered improved performances within its Hips and Knees arms due to the nature of the businesses.

Zacks Equity Research

What's in the Cards for Quidel (QDEL) This Earnings Season?

by Zacks Equity Research

Quidel (QDEL) is expected to have gained from its Molecular Diagnostic Solutions business in Q1.

Zacks Equity Research

Should You Buy Exact Sciences (EXAS) Ahead of Earnings?

by Zacks Equity Research

Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Varian (VAR) Earnings and Revenues Surpass Estimates in Q2

by Zacks Equity Research

Varian (VAR) continued to gain from core Oncology Systems segment in Q2.

Zacks Equity Research

Livongo Health (LVGO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Livongo Health (LVGO) first-quarter performance to reflect growth in core Livongo for Diabetes solution.

Zacks Equity Research

Luminex (LMNX) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.

Zacks Equity Research

What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter results likely to reflect solid performance at Pharmaceutical Distribution.

Nalak Das headshot

Buy 5 Top Stocks Set to Beat Earnings Estimates Tomorrow

by Nalak Das

Despite the negative earnings trend, a handful of stocks with a favorable Zacks Rank are poised to beat earnings estimates tomorrow.

Zacks Equity Research

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) will provide pipeline updates along with financial numbers for the first quarter in its impending earnings release.

Zacks Equity Research

What's in Store for Becton, Dickinson's (BDX) Q2 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.

Zacks Equity Research

OPKO Health (OPK) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

OPKO Health's (OPK) first-quarter performance is likely to reflect solid performance from Products and RAYALDEE.